Envafolimab before surgery for advanced rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests envalolimab (an immunotherapy) alone or with chemo (CAPEOX) before surgery for locally advanced rectal cancer. It aims to shrink the tumor and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have rectal cancer confirmed by a biopsy.
- Your cancer is at a certain stage (T3-4 N0-1, meaning it has grown into or through the bowel wall and may have spread to nearby lymph nodes).
- You are between 18 and 70 years old.
- Your cancer has not spread to other parts of the body.
- You do not have multiple primary tumors or severe weight loss/muscle wasting (cachexia).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new immunotherapy drug (Envafolimab) combined with standard chemotherapy before surgery for esophageal cancer that has not spread far. The goal is to see if this combination can shrink tumors and improve outcomes.
This trial tests giving radiation and chemotherapy plus an immunotherapy medicine called tislelizumab before surgery for locally advanced rectal cancer. It aims to shrink the tumor and increase the chance of fully removing it safely (R0 resection).
This trial tests whether adding a new immunotherapy drug (ivonescimab) to standard chemotherapy (CAPOX) before surgery can improve outcomes for people with locally advanced colon cancer. It compares the combination to chemotherapy alone.
This trial tests a combination of radiation, two immunotherapy drugs (iparomlimab and tuvonralimab), a targeted therapy (regorafenib), and chemotherapy (CAPOX) given before surgery for locally advanced rectal cancer. The goal is to see if this approach can shrink the tumor and improve outcomes for people whose tumors have normal mismatch repair proteins (pMMR/MSS).
This trial tests giving chemotherapy (mFOLFOXIRI) plus bevacizumab before surgery for rectal cancer that has higher-risk features. It aims to shrink or control the cancer early to improve outcomes after treatment.
This trial tests whether a short course of radiation before surgery, combined with the immunotherapy drug envafolimab and the chemo regimen CAPEOX, works better for shrinking locally advanced rectal cancer. It is aimed at people whose tumor is not “MMR-deficient” (it is pMMR/MSS), and it asks participants to be able to return for repeated checkups and treatments.
Hear when a new Colon Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.